Oral bovine type I collagen
Drug500 mcg of CI daily for 15 months
Other names: CI
NCT Number: NCT00005675
Diffuse systemic sclerosis (SSc), or scleroderma, is a connective tissue disease causing damage to skin and other organs. The purpose of this study is to determine if taking oral bovine type I collagen (CI) will improve the condition of SSc patients.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 2
University of Alabama at Birmingham, Birmingham, Alabama, United States
SSc is a chronic connective tissue disease that is caused by excess collagen deposits that damage the skin and other organs. This study will determine if a daily oral dose of bovine CI will improve the condition of patients with SSc.
Patients will be randomly assigned to one of two groups. The first group will receive 500 mcg bovine CI daily for 15 months; the second group will receive placebo. Study visits will be conducted at Months 4, 8, 12, and 15. Patients will undergo physical examination and blood tests at each visit. Patients will also be evaluated for modified Rodnan skin score (MRSS) and will be given health assessment questionnaires. A chest x-ray will be conducted at study entry and pulmonary function tests will be conducted at study entry and Month 12.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
500 mcg of CI daily for 15 months
Other names: CI
CI placebo daily for 15 months
Time frame: Measured at Month 12
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Nih
Multicenter Phase II Trial of Oral Type I Bovine Collagen in Scleroderma
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04464434
Autologous Stem Cell Transplantation, Connective Tissue Diseases
Milan, Italy
View Trial DetailsNCT04746313
Brain Diseases, Central Nervous System Diseases
Lille, France
View Trial DetailsNCT01570764
Connective Tissue Diseases, Fibrosis
Paris, France
View Trial DetailsNCT06772896
Behavior, Behavioral Symptoms
Montreal, Quebec, Canada
View Trial Details